Krystal Biotech Inc.

5 hours ago · marketbeat.com

Krystal Biotech NASDAQ: KRYS reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining updated timelines for several clinical programs and authorizing a share repurchase program of up to $400 million.

9 hours ago · globenewswire.com

$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome Strong balance sheet, ending the quarter with $1.2 billion in cash and investments Board authorizes share repurchase program of up to $400 million PITTSBURGH, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the third quarter ended September 30, 2026 and provided a business update. “Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline,” said Krish S.

7 days ago · zacks.com

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 days ago · globenewswire.com

PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update.

17 days ago · zacks.com

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.

18 days ago · globenewswire.com

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature Data will be presented by study investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 2026 PITTSBURGH, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today a positive clinical update supporting initial proof of concept for KB113, an intratumoral immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance, in the treatment of basal cell carcinomas (BCCs) in patients with Gorlin syndrome: Broad antitumor responses were detected in all three Gorlin syndrome patients treated with KB113, with over 80% of assessed BCC lesions reducing in size; Responses were observed in both injected and non-injected lesions, including substantial regression in lesions that were not directly injected with KB113, consistent with an abscopal effect; and Complete clearance of an injected lesion was also confirmed histologically for each of the three patients treated with KB113. Gorlin syndrome is a genetic disease characterized by a greatly increased risk of developing BCCs.

23 days ago · seekingalpha.com

Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2 revenue and expanding global reach. KRYS maintains a $1.1bn cash position, a 40% operating margin, and trades at ~12x forward P/E, supporting attractive valuation.

2 months ago · zacks.com

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

2 months ago · zacks.com

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

3 months ago · zacks.com

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.